Follistatin樣蛋白1（FSTL1）是一種廣泛表達(dá)的細(xì)胞外糖蛋白，homologously grouped into the osteonectin (BM-40/SPARC) family of secreted proteins based on its possession of both a follistatin-like and extracellular calcium-binding domain。FSTL1最初在克隆的小鼠成骨細(xì)胞系中鑒定為TGF-β誘導(dǎo)型蛋白質(zhì)，然后發(fā)現(xiàn)FSTL1參與一系列cell-type-specific功能，例如細(xì)胞擴增，分化，凋亡和遷移調(diào)節(jié)，以及許多生物過程，包括胚胎發(fā)育，炎癥反應(yīng)，血管生成，腫瘤發(fā)生和免疫疾病發(fā)病機制。FSTL1?Highly conserved across mammalian species并在人體組織中廣泛表達(dá)，可以通過先天免疫系統(tǒng)的信號傳遞介質(zhì)（例如TLR4激動劑和通過NFκB途徑的關(guān)節(jié)炎發(fā)生細(xì)胞因子IL-1β）上調(diào)，以刺激 pro-inflammatory cytokines（包括TNF-α，IL-1β，IL-6和IL-8）表達(dá)和分泌。盡管間充質(zhì)譜系的細(xì)胞能夠產(chǎn)生FSTL1，但在正常生理條件下，造血譜系細(xì)胞中明顯不存在FSTL1表達(dá)。然而，巨噬細(xì)胞和單核細(xì)胞能夠在炎癥部位吸收FSTL1，其中FSTL1刺激可以引起胱天蛋白酶-1的表達(dá)及其從pro-IL-1β酶切active IL-1β。盡管已經(jīng)指出FSTL1的過表達(dá)已經(jīng)被認(rèn)為是免疫疾病如類風(fēng)濕性關(guān)節(jié)炎（RA）和骨關(guān)節(jié)炎（OA）實質(zhì)進(jìn)展因素，但是FSTL1血清水平的降低已經(jīng)被確定為在卵巢癌和子宮內(nèi)膜癌發(fā)生中起重要作用，其中它直接影響細(xì)胞增殖，遷移和入侵。

BioGems人類FSTL1預(yù)包被ELISA（酶聯(lián)免疫吸附測定）試劑盒是采用固相免疫測定法，專門設(shè)計用于測量FSTL1，96孔板預(yù)包被有FSTL1特異性的小鼠單克隆抗體。它含有NS0表達(dá)的重組FSTL1。檢測抗體是對FSTL1特異性的生物素化山羊多克隆抗體。該試劑盒已經(jīng)過分析驗證，是即用型試劑。

?

?

Product Details

?

Components

?

Reproducibility

?

Follistatin-like protein 1 (FSTL1) is a widely-expressed, extracellular glycoprotein that is homologously grouped into the osteonectin (BM-40/SPARC) family of secreted proteins based on its possession of both a follistatin-like and extracellular calcium-binding domain. Initially identified as a TGF-β-inducible protein in a cloned mouse osteoblast cell line, FSTL1 has since been implicated in an array of cell-type-specific functions, such as the regulation of proliferation, differentiation, apoptosis and migration, as well as a number of biological processes, including embryonic development, inflammatory response, angiogenesis, tumorigenesis, and immune disease pathogenesis. Highly conserved across mammalian species and widely expressed in human tissues, FSTL1 can be upregulated through signaling mediators of the innate immune system,such as TLR4 agonists and the arthritogenic cytokine IL-1β via NFκB pathways, to stimulate the expression and secretion of pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6 and IL-8. While cells of mesenchymal lineage are capable of FSTL1 production, FSTL1 expression is notably absent from cells of hematopoietic lineage under normal physiological conditions. Macrophages and monocytes are, however, capable of taking up FSTL1 at sites of inflammation where FSTL1 stimulation can cause the expression of caspase-1 and its resultant enzymatic cleavage of active IL-1β from pro-IL-1β. Whereas the overexpression of FSTL1 has been noted as a substantial contributor to the progression of immune diseases like rheumatoid arthritis (RA) and osteoarthritis (OA), diminished FSTL1 serum levels have been identified as playing a significant part in both ovarian and endometrial carcinogenesis, where it directly affects cell proliferation, migration and invasion.

The BioGems Human FSTL1 Pre-Coated ELISA (Enzyme-Linked Immunosorbent Assay) kit is a solid phase immunoassay specially designed to measure FSTL1 with a 96-well strip plate that is pre-coated with mouse monoclonal antibody specific for FSTL1. It contains NS0-expressed recombinant FSTL1. The detection antibody is a biotinylated goat polyclonal antibody specific for FSTL1. The kit is analytically validated with ready to use reagents.